BB
Therapeutic Areas
AllerGene AI Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| In vivo mRNA CAR-T for Mast-Cell Driven Allergies | Severe allergic diseases and anaphylaxis | Pre-clinical |
Leadership Team at AllerGene AI Therapeutics
SK
Sid Kerkar, M.D.
CEO & Founder
AP
Alan Ponce, M.S.
Research Associate
PM
Pawel Muranski, M.D.
Lead Advisor